Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: A review

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 457-464

  Awad, Ahmed S ^a   Goldberg, Michael E ^a  

^a Department of Anesthesiology   (United States)

Author keywords

Antihypertensive medications; Calcium channel blocker; End organ damage; Hypertensive crisis; Hypertensive urgency

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLEVIDIPINE; ESMOLOL; FELODIPINE; GLYCERYL TRINITRATE; ISRADIPINE; LABETALOL; NICARDIPINE; NITROPRUSSIDE SODIUM; PLACEBO; PYRIDINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; AORTA DISSECTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD FLOW; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; ESSENTIAL HYPERTENSION; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPERTENSIVE CRISIS; HYPOTENSION; INOTROPISM; INTENSIVE CARE; LIVER FUNCTION; MEAN ARTERIAL PRESSURE; NAUSEA; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINUS TACHYCARDIA; TACHYCARDIA; THORAX PAIN; VOMITING; ACUTE DISEASE; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PERIOPERATIVE PERIOD;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CRITICAL CARE; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; PERIOPERATIVE CARE; PYRIDINES;

EID: 79952058569     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Varon J. Treatment of acute severe hypertension current and newer agents. Drugs. 2008;68(3):283-297.
2. Pollack C, Varon J, Garrison N, Ebrahimi R, Dunbar L. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med. 2009;53(3):329-338.
3. Deeks E, Keating G, Keam S. Clevidipine: a review of its use in the management of acute hypertension. Am J Cardiovasc Drugs. 2009;9(2):117-134.
4. Potter JF. Malignant hypertension in the elderly. Q J Med. 1995;88: 641-647.
5. National Heart, Lung, and Blood Institute. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC-7) 2003. Publication No. NIH 03-5233. Bethesda (MD): NIH; 2003.
6. Rhoney D, Peacock F. Intravenous therapy for hypertensive emergencies, part 1. Am J Health Syst Pharm. 2009;66:1343-1352.
7. Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emergencies. Prevalence and clinical presentation. Hypertension. 1996;27:144-147.
8. Slama M, Modeliar S. Hypertension in the intensive care unit. Curr Opin Cardiol. 2006;21:279-287.
9. Rodriguez G, Varon J. Clevidipine: a unique agent for the critical care practitioner. Crit Care Shock. 2006;9(2):37-41.
10. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007;131:1949-1962.
11. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
12. Aronson S, Dyke C, Stierer K, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107(4):1110-1121.
13. Bailey J, Lu W, Levy J, et al. Clevidipine in adult cardiac surgical patients a dose-finding study. Anesthesiology. 2002;96:1086-1094.
14. Prlesi L, Cheng-Lai A. Clevidipine: a novel ultra-short-acting calcium antagonist. Cardiol Rev. 2009;17:147-152.
15. Feldstein C. Management of hypertensive crises. Am J Ther. 2007; 14(2):135-139.
16. Weant KA, Flynn JD, Smith KM. Postoperative hypertension. Orthopedics. 2004;27:1159-1161.
17. Dasta JF, Bollinger JE, Gerlach AT, et al. National survey of acute hypertension management. Crit Care Med. 2007;35(12 Suppl):A89.
18. Desai R, Muntazar M, Goldberg M. Strategies for managing perioperative hypertension. Curr Hypertens Rep. 2009;11:173-177.
19. Murphy C. Hypertensive emergencies. Emerg Med Clin North Am. 2005; 13:973-1007.
20. Nordlander M, Sjoquist O, Ericsson H, et al. Pharmacodynamic, pharmacokinetics and clinical effects of clevidipine, a short acting calcium antagonist rapid blood pressure control. Cardiovasc Drug Rev. 2004;22:227-250.
21. Van Zwieten PA, van Wezel HB. Antihypertensive drug treatment in the perioperative period. J Cardiothorac Vasc Anesth. 1993;7:213-226.
22. Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis. 2004;47:34-57.
23. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol. 2000; 12:80-85.
24. Levy H. The ideal agent for perioperative hyprtension and potential cytoprotective effects. Acta Anaesthesiol Scand. 1993;37:20-25.
25. Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs. 2005;65(2 Suppl):1-10.
26. Segawa D, Sjoquist O, Nordlander M, Wang QD, Gonon A, Ryden L. Cardiac inotropic vs chronotropic selectivity of isradipine, nifedipine. agd clevidipine, a new ultrashort-acting dihydropyridine. Eur J Pharmacol. 1999;380(2-3):123-128.
27. Nordlander M, Bjorkman JA, Regardh CG, Thalen P. Pharmacokinetics and hemodynamic effects of an uItrashort-acting calcium antagonist. Br J Anaesth. 1996;76(1):A24.
28. Goyal M, Jandhyala BS. Splanchnic artery occlusion shock (SAO) in the rats. Effect of clevidipine and sodium nitroprusside on splanchnic hemodynamics. FASEB Exp Biol. 1997;97:A285.
29. Gourine A, Gonon A, Sjoquist P, et al. Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxiderelated mechanisms in the jeopardized myocardium. Cardiovasc Res. 2001;51:100-107.
30. Nguyen H, Ma K, Pham D, Pharm D. Clevidipine for the treatment of severe hypertension in adults. Clin Ther. 2010;32(1):11-23.
31. Cada D, Levien T, Baker D. Clevidipine butyrate injectable emulsion. Hosp Pharm. 2008;43(11):903-912.
32. Levy J, Mancao M, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007;105:918-925.
33. Schwieler H, Ericsson H, Lofdahl P, Thulin T, Kahan T. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol. 1999;34(2):268-274.
34. Eagle K, Berger P, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery - executive summary. A report of the American College of Cardiology/American Heart Association. Task force on practice guidelines comtask force on practice guidelines (committee to update the 1996 guidelines on perioperative cardiovascular evaluation for noncardiac surgery). Circulation. 2002;105:1257-1267.
35. Varon J, Marik PE. Clinical review: the management of hypertensive crises. Crit Care. 2003;7:374-384.
36. Varon J, Peacock W, Garrison N, et al. Prolonged infusion of clevidipine results in safe and predictable blood pressure control in patients with acute severe hypertension. Chest. 2007;132(4 Suppl):477.
37. Product Information: CLEVIPREX(R) IV Injection, Clevidipine Butyrate IV Injection. Clayton (NC): Hospira, Inc.; 2008.
38. Ericsson H, Tholander B, Regardh CG. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolized by esterases in different animal species and man. Eur J Pharm Sci. 1999;8(l):29-37.
39. Peacock W, Angeles J, Soto K, Lumb P, Varon J. Parenteral clevidipine for the acute control of blood pressure in the critically ill patient: a review. Ther Clin Risk Manag. 2009;5:627-634.
40. Ericsson H, Schwieler J, Lindmark BO, Lofdahl P, Thulin T, Regardh CG. Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients. Chirality. 2001;13:130-134.
41. Ericsson H, Fakt C, Hoglund L, et al. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Eur J Clin Pharmacol. 1999;55(l):61-67.
42. Vylsteke A, Milner Q, Ericsson H, et al. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, in cardiac surgical patients during cardiopulmonary bypass. Br J Anaesth. 2000;85:683-689.
43. Ericsson H, Bredberg U, Enksson U, Jolin-Mellgard A, Nordlander M, Regardh CG. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology. 2000;92(4):993-1001.
44. Hussar AD. New therapeutic agents marketed in the second half of 2008. Pharm Today. 2009;15(2):37-48.
45. Singla N, Warltier D, Gandhi S, et al. Treatment of acute postoperative hypertension in cardiac surgery patients: an Efficacy Study of Clevidipine Assessing its Postoperative Antihypertensive Effect in Cardiac Surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2008;107(1):59-67.